Nalaganje...
Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost‐effectiveness study
AIMS: Patients with metastatic gastrointestinal stromal tumours (GIST) are treated in first line with the oral tyrosine kinase inhibitor, imatinib, until progressive disease. With this fixed dosing regimen, only approximately 40% of patients reach adequate plasma levels within the therapeutic index....
Shranjeno v:
| izdano v: | Br J Clin Pharmacol |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
John Wiley and Sons Inc.
2019
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6710511/ https://ncbi.nlm.nih.gov/pubmed/31112617 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13990 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|